Articles On Patrys (ASX:PAB)

“This quarter has delivered a period of significant momentum for Patrys. We have continued to build the portfolio of data for deoxymabs which has further expanded the broad and promising utility for our antibody assets in addition to meetin...

Patrys (ASX:PAB) has announced data from its completed pre-clinical study that has demonstrated that its full-sized deoxymab antibody, PAT-DX3, can be used as a targeting agent for antibody-drug conjugates to deliver anti-cancer dru...

It’s been a busy morning for the ASX Healthcare sector, with plenty of positive announcements for investors to digest. But the Health Index (XHJ) is trading down by 0.5% at the time of writing, compared to the broader index which is trading...

“This preclinical study has shown that the affinity our deoxymabs have for DNA is sufficient for them to target the delivery of cancer drugs to tumours where they can inhibit tumour growth and improve survival," says CEO.

Patrys (PAB) has shown its antibody can be used as a targeting agent to deliver anti-cancer drugs to tumours A recently completed pre-clinical study demonstrated mice treated with the company’s full-sized deoxymab antibody, PAT-DX3, showed...

Both Amplia and Patrys have flagship drugs in development that take unique approaches to tackling cancers.

Its primary focus is to move its lead asset, PAT DX1, a small antibody fragment, to the first human clinical trial and it is confident of hitting this milestone in late 2022. 

Its primary focus is to move its lead asset, PAT DX1, a small antibody fragment, to the first human clinical trial and it is confident of hitting this milestone in late 2022. 

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

Local stocks lost ground on Thursday as a tone of caution emerged in Asian trade, ahead of the US Federal Reserve’s annual symposium, which is set to kick off on Friday night. The ASX 200 finished 0.54% lower and in a theme that has held co...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

Trading Places is Stockhead’s recap of the buys and sells of ASX small cap shares by fund managers and other famous investors over the last fortnight. Specifically, Stockhead tracks substantial shareholder movements, being shareholders hold...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

The ASX closed in negative territory despite a solid gain in tech stocks. The ASX 200 closed 0.23% down at 7,474 points although the ASX Emerging Companies Index rose 1.06% to close at 2,226 points. Despite tech stocks gaining 4.38%, as inv...

Patrys Limited (ASX: PAB) shares are tumbling in late morning trade. At the time of writing, the Patrys share price has slumped 16.33% following the company’s latest announcement. Below we take a look at the ASX healthcare company’s update...

ASX 200 health stocks index fell by 0.12% this morning, compared to the broader index which fell by 0.19%. A class action proceeding against Mayne Pharma (ASX:MYX) has been brought by Phi Finney McDonald on behalf on investors who bought MY...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Patrys (ASX:PAB) says new preclinical data from the Garvan Institute of Medical Research has shown that its’ deoxymab antibody PAT-DX1 is able to slow tumour growth and increase survival in an animal model of pancreatic cancer....

ASX 200 health stocks index rose by 0.68% this morning, compared to the broader index which rose by 0.24%. Respiratory device specialist, 4D Medical (ASX:4DX), led the pack, rising by 7%. In its quarterly update,  the company said it has ra...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

Therapeutic antibody development company Patrys (ASX:PAB) has announced new data from non-clinical studies have confirmed its full-sized IgG deoxymab antibody, PAT-DX3, is able to cross the blood-brain barrier in an animal model of...

The Patrys Limited (ASX: PAB) share price is starting the week on a strong note. This comes after the therapeutic antibody development company announced new data from non-clinical studies of its cancer-fighting antibody, PAT-DX3. Patrys is...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Each week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Relative Strength Index (RSI). The RSI is a technical gauge which measures how trading momentum is affecting the price action. A reading of 70 is seen as the le...

Ask A Fund Manager The Motley Fool chats with fund managers so that you can get an insight into how the professionals think. In part 1 of our interview, 1851 Capital portfolio manager Martin Hickson tells us the telecommunications company...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

Fertoz Ltd (ASX:FTZ) topped the pops with a red hot 14-day RSI of 93 after two massive days to finish the week. A total of 18 ASX companies posted a 14-day RSI above 70 last week, down from 25 in the week prior. Each week, Stockhead recaps...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

Summary After the launch update of Aussie BubsTM-branded formula range on Walmart.com, the BUB share price shot up by 29.3%. Today, the AWN share price surged 27.5% to AU$1.02, clocking a heavy volume of over 1.7 million shares. The m...

Recent advances in our still-shallow understanding of the human brain have led to a renewed interest in companies that focus on neuroscience. The most famous neuroscience startup, Elon Musk’s Neuralink, is probably the first company that co...

Summary The ASX 200 breached 7,400 level for the first time to hit a fresh high of 7,406.20. The index closed 6.70 points higher at 7,386.20 ahead of the US Fed meeting scheduled tonight. The widely anticipated US Fed policy statement...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

Summary Neuroprotective drug developer Argenica Therapeutics commenced trading on the ASX after a well-supported AU$7 million capital raising. The Company disclosed that the ASX listing would allow it to develop its novel neuroprotecti...

Summary The ASX 200 was trading higher by 12.70 points or 0.17% at 7315.20 by mid-session, led by tech, materials and telecom stocks. The Information Technology sector was the top performer, tracking overnight gains in the tech-heavy N...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

It was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies releasing seperate announcements that sent their share prices higher. Cancer therapy stocks Invion (ASX:IVX), Immutep (ASX:IMM), and Imugene (ASX...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scrol...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade.   WINNERS Scr...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest movers – the winners and losers alike. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday t...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Summary Two directors of Australia’s Crown Resorts Ltd (ASX:CWN) resigned just a day after a report deemed the casino giant unfit to hold a gambling licence for its new Sydney resort. The report by the New South Wales state’s gambling...

Summary Melbourne based biotech company Patrys Limited has selected an optimised stable cell line for the development of PAT-DX1. With the selection of the stable and high-yield cell line, the Company will establish largescale manufact...

Summary After raising A$7.3 million via a placement, the company is now sufficiently funded to accelerate its development programs. During the quarter, the company reported a net cash outflow of A$667k from the operating activities. T...

The funds raised through the placement and rights issue will position the company to effectively leverage the wide range of therapeutic opportunities provided by its unique Deoxymab platform.

Therapeutic antibody development company Patrys (ASX:PAB) has announced the Australian patent titled 'Antibody-mediated Autocatalytic, Targeted Delivery of Nanocarrier to Tumors' has been granted.

Therapeutic antibody development company Patrys (ASX: PAB) has been granted an Australian patent covering the use of its novel Deoxymab platform conjugated to nanoparticles (NP) for the targeted delivery of anti-cancer drugs. The patent is...

Australian antibody development company Patrys (ASX:PAB) says it has completed initial production and characterisation of PAT-DX3, a full-sized, humanised antibody version of its dimerised antibody fragment PAT-DX1.

A quick wrap of the ASX’s key winners and losers on Wednesday, September 16. Data is taken after the market closes at 4pm AEST. Stocks highlighted in yellow made potentially market-moving announcements during the day. WINNERS TICKE...